---
title: "ZHONGSHENGYAOYE: The first participant has been enrolled in the Phase III clinical trial of RAY1225 injection for glycemic reduction"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254775556.md"
description: "ZHONGSHENGYAOYE announced that its holding subsidiary ZHONGSHENGRUICHUANG has completed the enrollment and administration of the first participants in two Phase III clinical trials for the innovative peptide drug RAY1225 injection, which is independently developed. RAY1225 injection is a peptide drug with global independent intellectual property rights and has the potential for long-acting administration every two weeks. ZHONGSHENGRUICHUANG will continue to advance the Phase III clinical trials of RAY1225 injection, striving to complete the relevant research and apply for drug market approval as soon as possible"
datetime: "2025-08-27T09:46:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254775556.md)
  - [en](https://longbridge.com/en/news/254775556.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254775556.md)
---

# ZHONGSHENGYAOYE: The first participant has been enrolled in the Phase III clinical trial of RAY1225 injection for glycemic reduction

ZHONGSHENGYAOYE announced that its holding subsidiary ZHONGSHENGRUICHUANG has completed the enrollment and administration of the first participant in two Phase III clinical trials for the innovative peptide drug RAY1225 injection, which is independently developed. RAY1225 injection is a peptide drug with global independent intellectual property rights and has the potential for long-acting administration every two weeks. ZHONGSHENGRUICHUANG will continue to advance the Phase III clinical trials of RAY1225 injection, striving to complete the relevant research and apply for drug market approval as soon as possible

### Related Stocks

- [002317.CN](https://longbridge.com/en/quote/002317.CN.md)

## Related News & Research

- [20:38 ETHyundai Bioscience Discloses XAFTY®'s IC50 Data for Ebola--"Secured Scientific Evidence for Immediate Treatment"](https://longbridge.com/en/news/287135394.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [US working with small biotech firm on experimental Ebola treatment, Bloomberg News reports](https://longbridge.com/en/news/287108072.md)
- [ZAWYA: Dubai Autodrome, a subsidiary of Union Properties, closes standout season with 88,700+ experiences and major events line-up](https://longbridge.com/en/news/287043713.md)
- [Andritz wins Sanitex order for two diaper lines, sanitary napkin line in Congo](https://longbridge.com/en/news/287166384.md)